May 20, 2020 / 5:08 AM / 6 days ago

BRIEF-Santhera Pharmaceuticals Completes Enrollment Of Phase 3 Sideros Study With Puldysa

May 20 (Reuters) - Santhera Pharmaceuticals Holding AG :

* COMPLETES ENROLLMENT OF PHASE 3 SIDEROS STUDY WITH PULDYSA® (IDEBENONE) IN DUCHENNE MUSCULAR DYSTROPHY (DMD) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below